Relay Therapeutics Stock Performance
| RLAY Stock | USD 8.65 0.27 3.03% |
On a scale of 0 to 100, Relay Therapeutics holds a performance score of 11. The company holds a Beta of 0.79, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Relay Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Relay Therapeutics is expected to be smaller as well. Please check Relay Therapeutics' value at risk, as well as the relationship between the kurtosis and price action indicator , to make a quick decision on whether Relay Therapeutics' historical price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Relay Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Relay Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (3.03) | Five Day Return (0.92) | Year To Date Return 5.75 | Ten Year Return (75.32) | All Time Return (75.32) |
1 | Do New Board Appointments Signal a Strategic Shift for Relay Therapeutics as Cash Outlook Improves | 11/11/2025 |
2 | Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS... | 12/12/2025 |
3 | Why Relay Therapeutics Stock Rocketed Nearly 15 percent Higher This Week - MSN | 12/29/2025 |
4 | Acquisition by Patel Sanjiv of 994 shares of Relay Therapeutics at 2.99 subject to Rule 16b-3 | 12/31/2025 |
5 | Disposition of 43168 shares by Patel Sanjiv of Relay Therapeutics at 7.82 subject to Rule 16b-3 | 01/06/2026 |
6 | Top Executive Makes Major Move With Relay Therapeutics Stock - TipRanks | 01/07/2026 |
7 | Acquisition by Thomas Catinazzo of 400000 shares of Relay Therapeutics at 7.94 subject to Rule 16b-3 | 01/13/2026 |
8 | Relay Therapeutics, Inc. Given Average Recommendation of Moderate Buy by Brokerages - MarketBeat | 01/21/2026 |
9 | Disposition of 1695 shares by Thomas Catinazzo of Relay Therapeutics at 8.45 subject to Rule 16b-3 | 01/28/2026 |
10 | Oppenheimer Notes Relay Therapeutics Pipeline Strength in Mutant-Selective Inhibitors | 02/02/2026 |
11 | Relay Therapeutics to Participate in Guggenheim Emerging Outlook Biotech Summit 2026 | 02/04/2026 |
12 | Relay Therapeutics Insider Sells 21,000 Shares for 166,700 After 65 percent Run | 02/06/2026 |
13 | Why Relay Therapeutics Is Up 9.4 percent After FDA Breakthrough Tag For Breast Cancer Combo | 02/09/2026 |
| Begin Period Cash Flow | 146.4 M | |
| Total Cashflows From Investing Activities | -41.1 M |
Relay Therapeutics Relative Risk vs. Return Landscape
If you would invest 617.00 in Relay Therapeutics on November 12, 2025 and sell it today you would earn a total of 248.00 from holding Relay Therapeutics or generate 40.19% return on investment over 90 days. Relay Therapeutics is currently generating 0.6672% in daily expected returns and assumes 4.6654% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Relay, and 87% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Relay Therapeutics Target Price Odds to finish over Current Price
The tendency of Relay Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 8.65 | 90 days | 8.65 | about 10.03 |
Based on a normal probability distribution, the odds of Relay Therapeutics to move above the current price in 90 days from now is about 10.03 (This Relay Therapeutics probability density function shows the probability of Relay Stock to fall within a particular range of prices over 90 days) .
Relay Therapeutics Price Density |
| Price |
Predictive Modules for Relay Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Relay Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Relay Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Relay Therapeutics is not an exception. The market had few large corrections towards the Relay Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Relay Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Relay Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.37 | |
β | Beta against Dow Jones | 0.79 | |
σ | Overall volatility | 0.75 | |
Ir | Information ratio | 0.08 |
Relay Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Relay Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Relay Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Relay Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 10.01 M. Net Loss for the year was (337.71 M) with loss before overhead, payroll, taxes, and interest of (259.24 M). | |
| Relay Therapeutics currently holds about 1.05 B in cash with (249.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Relay Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Why Relay Therapeutics Is Up 9.4 percent After FDA Breakthrough Tag For Breast Cancer Combo |
Relay Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Relay Stock often depends not only on the future outlook of the current and potential Relay Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Relay Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 142.9 M | |
| Cash And Short Term Investments | 781.3 M |
Relay Therapeutics Fundamentals Growth
Relay Stock prices reflect investors' perceptions of the future prospects and financial health of Relay Therapeutics, and Relay Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Relay Stock performance.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (38.87) % | ||||
| Current Valuation | 982.93 M | ||||
| Shares Outstanding | 173.32 M | ||||
| Price To Book | 2.54 X | ||||
| Price To Sales | 184.90 X | ||||
| Revenue | 10.01 M | ||||
| Gross Profit | (259.24 M) | ||||
| EBITDA | (380.21 M) | ||||
| Net Income | (337.71 M) | ||||
| Cash And Equivalents | 1.05 B | ||||
| Cash Per Share | 8.72 X | ||||
| Total Debt | 48.5 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 15.22 X | ||||
| Book Value Per Share | 3.52 X | ||||
| Cash Flow From Operations | (249.11 M) | ||||
| Earnings Per Share | (1.72) X | ||||
| Market Capitalization | 1.54 B | ||||
| Total Asset | 871.3 M | ||||
| Retained Earnings | (1.74 B) | ||||
| Working Capital | 758.48 M | ||||
About Relay Therapeutics Performance
Evaluating Relay Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Relay Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Relay Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.45) | (0.47) | |
| Return On Capital Employed | (0.52) | (0.55) | |
| Return On Assets | (0.45) | (0.47) | |
| Return On Equity | (0.50) | (0.47) |
Things to note about Relay Therapeutics performance evaluation
Checking the ongoing alerts about Relay Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Relay Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Relay Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 10.01 M. Net Loss for the year was (337.71 M) with loss before overhead, payroll, taxes, and interest of (259.24 M). | |
| Relay Therapeutics currently holds about 1.05 B in cash with (249.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Relay Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Why Relay Therapeutics Is Up 9.4 percent After FDA Breakthrough Tag For Breast Cancer Combo |
- Analyzing Relay Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Relay Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Relay Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Relay Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Relay Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Relay Therapeutics' stock. These opinions can provide insight into Relay Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.